Clinical Trial Update: The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing sustained-release versus immediate-release pramipexole for nocturnal symptoms in advanced Parkinson disease patients on L-Dopa has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pramipexole (pramipexole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 4 | Status: COMPLETED | Results posted: 2021-02-16